Related Posts

Emcure Pharma Q1 profit jumps 36%, revenue rises 23%; appoints Samit Mehta as COO

“We have begun FY27, the second year of our five-year plan—on a strong footing. FY26 was about putting the building blocks in place across teams, portfolio, integration and operating discipline. FY27 is about delivery, and Q1 is an encouraging early signal,” said Satish Mehta, Managing Director and CEO Emcure Pharmaceuticals.